GW Pharma (GWPH) Reports Q4 Loss of GBP0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharma (GWPH) Announces Publication of Positive Physician Reports on Epidiolex Effect, Safety
December 7, 2015 2:03 PM ESTGW Pharmaceuticals plc (Nasdaq: GWPH) announced new physician reports of clinical effect and safety associated with the Epidiolex® (Cannabidiol or CBD) expanded access program. These data were presented by study authors at the American Epilepsy Society Annual Meeting (AES) in Philadelphia, PA1,2.
"We are pleased to report these promising data on significant numbers of children," said lead author Orrin Devinsky, M.D., of New York University Langone Medical Center's Comprehensive Epilepsy Center. "These data reinforce and support the safety and efficacy we have shared in previous studies. Most importantly it is... More
